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wall injury in C57BIJ6J mice and ApoE-/-mice. Treatment with MEG reduced neointimal 
thickening only in C57BIJ6J mice, suggesting a selective role for iNOS. In addition, ciga- 
rette smoking and hypercholesterolemia may have a synergistic effect on oxidative 
stress response to arterial injury in mice. 
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1177-87 The Protective Effect of the T(-107)C Promoter 
Polymorphiam of the Paraoxonase Gene in Arterial 
Thrombotic Disease 
Barbara Voetsch, Kelly S. Benke, Benito P. Damasceno, Lucia H. Siqueira, Joseph 
Loscalzo, Boston University Medical Center, Boston, Massachusetts, State University of 
Campinas, Campinas, Brazil. 
Background: Approximately one-third of patients with arterial thrombotic disease do not 
have traditional cardiovascular risk factors. Serum paraoxonase (PON) is an HDL-asso- 
ciated esterase that hydrolyzes products of lipid peroxidation and prevents the oxidation 
of LDL. PON levels are significantly reduced in patients with coronary heart disease. 
Recently, two PON promoter polymorphisrns, T(-107)C and G(-624)A, were identified 
that are consistently associated with lower PON expression and activity; however, it is 
not known if these polymorphisms are a risk factor for arterial thrombotic disease. 
Methods: We studied the PON promoter genotypes and vascular risk factors of 115 
patients (63 women, mean age: 35.8 _+ 6.9 years) with a clinically and radiologically 
defined arterial ischemic stroke occurring before the age of 45 years and 117 age- and 
gender-matched controls. To identify the T(-107)C polymorphism, we used non-radioac- 
tive single-strand conformational polymorphism analysis of a 129 bp-sized fragment con- 
taining the polymorphic site. 
For detection of the G(-824)A polymorphism, a 200 bp fragment was amplified using a 
mutagenic primer, resulting in an artificial restriction site for Pvu II when the polymorphic 
G nucleotide was present. 
Results: When analyzing the PON T(-107)C polymorphism, we found that the TT geno- 
type was significantly less frequent among patients than controls (12.2% vs. 22.2%, 
P=0.041). In a logistic regression model adjusting for arterial hypertension, smoking, dia- 
betes mellitus and hyperlipoproteinemia, this association remained significant 
(P=0.0297, OR=0.41,95% CI 0.19 to 0.9). Regarding the PON G(-824)A polymorphism, 
there was no significant difference between groups (P=0.47). 
Conclusion: These findings suggest that the PON -107T allele may have a protective 
effect against arterial thrombotic disease in young adults. Studies including a larger num- 
ber of patients and analyzing the effect of PON on atherothrombosis are necessary to 
understand better the mechanistic role of these observations in the development of arte- 
rial disease in the young. 
1177-88 Variability in Inhibition of Platelet Aggregation With 
Clopidogrel and Correlation With ADP-Induced P- 
Selectin Expression on Platelets 
Michael Anaioi, Pierre Theroux, Marta Ghitescu, Richard Gallo, Many Frojmovic, 
Montreal Heart Institute, Montreal, Quebec, Canada. 
Background: Thienopyridines inhibit platelet activation and aggregation by blocking the 
ADP P2Y12 receptor. We investigated the correlation between platelet aggregation and 
activation in patients treated with clopidogrel. 
Methods: Patients (n=19) with stable angina were assessed before and after 1 week 
treatment with 75 mg of clopidogrel given daily. Blood samples were anticoagulated with 
PPACK-hirudin. Platelet aggregation (TA) in stirred platelet rich plasma (PRP) and micro- 
aggregate formation (PA) in 1:10 diluted PRP at a shear stress of 1000s "1 were studied. 
In addition, flow cytometry was used to measure platelet activation, (P-selectin for secre- 
tion; and PAC-1 for free activated GPIIb/llla) after 10 p.M ADP stimulation. 
Results: Treatment by clopidogrel significantly reduced aggregation for both TA (65-+8 vs. 
45+15%, p<0.0001 ) and PA (84+8 vs. 49_+18 %, p<0.0001 ). Inhibition varied widely, from 
0 to 65% for TA; and from 0 to 70% for PA. Clopidogrel significantly decreased P-selectin 
expression (40±15 vs. 14±8%, p<0.0001) as well as PAC-1 binding (60±30 vs. 23+~?.0, 
p<0.001), By Linear regression analysis the magnitude of inhibition of platelet aggrega- 
tion correlated weakly with PAC-1 levels (R-square=0.17, p=0.08 for both TA and PA), 
but strongly with inhibition of P-selectin expression (R-square=0.28, p<0.02 and R- 
square=0.40, p<0.004, respectively). When inhibition of aggregation attained levels 
greater than 30% for TA and 25% for PA, P-selectin was always expressed by less than 
20% of platelets. 
Conclusion: Inhibition of platelet aggregation by clopidogrel was found to be highly vari- 
able. Inhibition may depend less on reduced free activated GPIIb/llla, where few recep- 
tors may be required to support aggregation, and more on reduced secreted adhesive 
ligands, Determination of P-selectin may be helpful to assess the anti-aggregant efficacy 
of clopidogrel. 
1177-89 The Relationship Between Serotonin 2A Receptor Gene 
Polymorphiems and Serotonin Induced Platelet 
Aggregation 
Masakatsu Shirnizu. Hozuka Akita, Nobuyuki Shiga, Eiji Takai, Chikao Iwai, Yoshitomo 
Miyamoto, Yukie Jyoukei, Shunichi Kumagai, Masayoshi Hashimoto, Mitsuhiro 
Yokoyama, Division of Cardiovascular and Respiratory Medicine, Kobe University 
Graduate School of Medicine, Kobe, Japan, Division of General Medical Science, Kobe 
University Graduate School of Medicine, Kobe, Japan. 
Background: Serotonin (5-HT) induces platelet aggregation (PA) and increases the vas- 
cular tonus through 5-HT2A receptor activation. Recently two common polymorphisms in 
the 6-HT2A receptor gene, T102C in exon 1 and -1438NG in the promoter, was identi- 
fied. We and others showed that these polymorphisms were associated with myocardial 
infarction or psychological disorder, However, these functional significance remains 
unknown. 
Methods: We investigated 5-HT2A receptor gene polymorphisms by PCR-RFLP and PA 
by using a novel laser-light scattering method in 33 young healthy volunteers (mean age 
26.4_+1.5SD). PA was induced by 5-HT 0.3, 1.0~M and ADP 0.1, 0.3HM, and evaluated 
by the peak of small aggregation counts. 
Results: (1)T102C polymorphism: The peak of PA induced by 5-HT in TT genotype was 
significantly higher compared with TC and CC genotype (Table), However, this polymor- 
phism did not influence ADP-induced PA. 5-HT concentration in platelet rich plasma 
(PRP) was not different between 2 groups. 
(2)-1438A/G polymorphism: A allele frequencies were 0.59 (AA: n=9, AG: n=21, GG: 
n=3). 5-HT-induced PA was not different between 2 groups (AA vs. AG+GG: 5-HT 0.31~M; 
30.8+11.4SEMx103 vs. 21.5+6.6SEM×103, NS, 5-HT 1.0~M;128.7+17.6SEM×103 vs. 
90.9~_12.2SEM×103, NS ). In addition, this did not influence ADP-induced PA. 
Conclusion: The T102C polymorphism was associated with 5-HT-induced PA, but the - 
1438A/G was not. This is the first report demonstrating the functional significance of the 
T102C polymorphism. 
T1O2C polymorphlsm, platelet aggregation, end 5-HT concentration in PRP 
TT(n=5) TC+CC(n=22+6) p 
5-HT 0.311M, x103 51.2±15.1 19.2±5.8 <0.05 
5-HT 1 .OHM, ×103 168.0±10.2 89.3±10.6 <0.005 
ADP 0.1~M, xl03 15.5±6.7 15.8¢5.4 NS 
ADP 0.3~M, xl03 161.2±25.9 92.7±14.3 NS 
5-HT in PRP, I~g/ml 0.28±0.01 0.26±0.02 NS 
1177-90 Increased Tissue Plasminogen Activator Antigen Is 
Predictive of Cardiovascular Events in the Veterans 
Affairs HDL Intervention Trial (VA-HIT) 
Geoffrev H. Taller, Sander J. Robins, Dorothea Collins, Izabela Lipinska, Prakash C. 
Deedwania, Hanna C. Rubins, Royal North Shore Hospital, Sydney, Australia. 
Background: Hemostatic factors have been shown to be predictive of future cardiovascu- 
lar disease events (CVD), although this has not been well studied in patients with known 
CVD and low HDL-CholesteroL 
Methods: We prospectively studied 829 subjects who were enrolled in the Veterans 
Affairs HDL Intervention Trial (VA-HIT). Enrolment criteria included known CVD and low 
HDL-cholesteroL Tissue plasminogen activator (TPA) antigen, factor VII antigen and 
fibrinogen were determined at baseline and after 1 year of therapy with placebo or gemfi- 
brozil. There was no effect of gemfibrozil on these measures of hemostasis. Thus, data 
from the gemfibrozil and placebo arms were combined. 
Results: During follow-up (median 5.1 years),140 patients had as a first event nonfatal MI 
or cardiac death. Relative risks (RR) were determined by multivariate Cox models, 
adjusting for age, hypertension, diabetes, smoking, body mass index, compliance and 
treatment. 
Results: Higher tPA antigen levels were associated with increased cardiovascular risk 
(4.7% for each unit tPA increase), whereas fibrinogen and factor VII were not significant 
predictors. 
Conclusion: Reduced fibrinolytic potential, as evidenced by increased tPA antigen levels, 
was a significant predictor of cardiovascular events in patients with known CVD and low 
HDL. Measurement of tPA may provide prognostic value in this subjects. Strategies to 
improve fibrinolytic potential in this population warrant further investigation. 
MI/Cardiac Death 
RR 95% CI p-value 
tPA antigen (ng/ml) 1.047 1.004-1.092 0.03 
Factor VII antigen (%) 1.002 0.990-1.014 0.78 
Fibrinogen (mg/dl) 0.999 0.996-1.002 0.90 
1177-91 Investigation of Thrombocytopenla In Individuals 
Receiving GPIIb-Illa Antagonist Therapy 
Lisa K. Jenninos. Steven Slack, Shila Cholera, Melanie White, Lou Ann Keith, Mary V. 
Jacoski, Sophie Combe, University of Tennessee Health Science Center, Memphis, 
Tennessee. 
Background: The use of GPfib-Illa antagonists for treatment of acute coronary syn- 
dromes continues to rise, as studies consistently demonstrate a significant benefit in 
reducing ischemic endpoints, Thrombocytopenia (TCP) is an infrequent, yet serious 
potential side effect of GPIIb-Illa antagonists. Little is known about the mechanism 
behind its development, therefore it is often impossible to predict which patient is at risk 
at the treatment onset. These patients are also concurrently treated with several drugs 
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(e.g., heparin) that could potentially be a factor in the TCP. In this study, we attempted to 
elucidate the mechanism behind the development of TCP following exposure to a small 
peptide GPIIb-Illa antagonist, RPR109891 (Klerval). Methods: Blood samples from 102 
patients who developed TCP during 5 clinical trials of Klerval were analyzed and com- 
pared with samples from patients treated with Klerval who did not develop TCP, control 
patients exposed to placebo only, and normal controls. TCP was defined as a platelet 
count <100,000/mm3 or any drop >40% compared to baseline. ELISA and Western blot 
analyses were employed to assess for the presence of GPIIb-Illa antibodies and to deter- 
mine whether the presence of drug was necessary for antibody binding. Results: These 
assays found that 30% of TCP patients developed antibodies to GPIIb-Illa upon expo- 
sure to Klerval or its active metabofite, RPR109039. Also, more than half of the 
RPR109039-dependent antibodies generated had increased binding in the presence of 
drug. Western blot analyses confirmed binding of drug dependent antibodies to proteins 
in the GPIIb-Illa molecular weight range. Also, we found that seven patients (7%) with 
documented TCP had hepadn-dependent antibodies by the Asserechrom HPIA and GTI- 
PF4 ELISA assays. HIPA, which depends upon a platelet aggregation response, is an 
inconclusive test in the presence of GPIIb-Illa antagonists. Conclusion: This study indi- 
cates that RPR109039-dependent antibodies have an increased propensity to bind 
GPIIb-Illa ligand-induced binding sites (LIBS). When TCP occurs in patients receiving 
antiplatelet and anticoagulant herapies, all potential causative agents should be investi- 
gated. 
1177-92 Effect of Arterial Stiffness on Platelet Activation 
Fumivasu Yamaseki. Takashi Furuno, Masanod Nishinaga, Kyoko Sato, Dongmei Zhang, 
Miss Nakagawa, Tadashi Ueta, Takayuki Sato, Yoshinod Doi, Tetsuro Sugiura, Clinical 
Laborsto~ Medicine and Geriatrics, Physiology, Kochi Medical School, Nankoku, Kochi, 
Japan. 
Increased arterial stiffness is strongly associated with atherosclerosis, and platelet acti- 
vation is important initial step causing thrombotic events in patients with atherosclerosis. 
However, little is known about the effect of arterial stiffness on platelet activation. There- 
fore, this study was undertaken to evaluate the effect of arterial stiffness on platelet func- 
tion in 38 normal volunteers (20 males and 18 females), aged 23 - 77yrs (mean = 
49±15yrs). Arterial stiffness was assessed by measuring heart - dght brechial artery and 
heart - dght ankle pulse wave velocity (PWV, m/sac). Flow cytometric analyses were per- 
formed to evaluate platelet activation by measuring surface expression of P-selectin (%) 
and platelet-neutrophil complex (PNC, %) before and after activation by adenosine 
diphospate (ADP). 
Results (1) Each PWV had a significant positive correlation with age. The level of P- 
selectin and PNC also had a positive correlation with age. (2) Multiple regression analy- 
sis using 2 variables (age and each PWVs) showed that PNC and P-selectin were signif- 
icantly related to PWVs, but there were no significant relation with age. 
Concluelon The platelet activation was affected by arterial stiffness, which suggests that 
arterial stiffness may play an important role on thrombotic events in patients with athero- 
sclerosis. 
PNC PNC (ADP) PNC (ADP) P-selectin (ADP) 
heart-brachial artery PWV 2.86* 6.95** 0.75 6.54** 
Age 0.04 0.09 0.01 -0.60 
heart-right ankle PWV 0.79* 6.95** 0.28 1.75* 
Age 0.04 0.08 -0.004 -0.50 
*p<0.05, **p<0.01 
1177-93 Activated Factor Xll (FXlla) Predicts Recurrent 
Troponin-T Positive Cardiac Events Following an Acute 
Myocardial Infarction 
Heidi Grundt, E~yvind Hetland, Annette Knudsen, Dennis W. Nilsen, Central Hospital in 
Rogaland, Stavanger, Norwa~ 
Background: Activated factor Xll (FXlla) participates in inflammation, thrombosis and 
fibrinolysis, and is involved in vascular injury and repair. 
Methods: We compared the recurrency of TnT positive coronary events in the upper 
quartile of FXlla (> 2,23 ng/mL) to the eventrate below the 75% percentile during a 
median follow-up period of 1,5 years in patients with an acute myocardial infarction. Tis- 
sue factor (TF), fibrin monomer (FM) and ultrasensitive C-reactive protein (IICRP) were 
also evaluated in relation to prognosis. Blood samples were drawn 4-6 days after myo- 
cardial infarction in 300 patients. Analyses of FXlla, TF and FM were performed by 
ELISA-methodology. 
Results: Sixty-two patients suffered an adverse TnT positive event during the follow-up 
period. In the upper quartile of FXIla (n=74), 32,4% had a secondary TnT positive cardiac 
event, as compared to 16,9% in the three lower quartiles of FXIla (n=225), p=0,008. The 
relative risk of recurrent TnT positive cardiac events was 92% higher for participants with 
FXlla concentrations in the upper quartile as compared to those with concentrations 
below the 75% percentile (relative risk 1,92 [95% CI 1,24-2,98]). Moreover, significantly 
higher FXlta levels were observed among subjects with recurrent TnT positive events as 
compared to those without (p=0,039). Furthermore, TnT positive recurrent events 
occurred earlier in the upper as compared to the lower quadiles (log-rank test; p=O,003). 
Significant differences in recurrent events were not observed between upper and lower 
quadiles of TF, FM or pCRP. In the upper quartile of FXIla, 61,9% of patients with a previ- 
ous history of myocardial infarction suffered a secondary TnT positive event, as com- 
pared to an eventrate of 20,4% in patients with no history of myocardial infarction, 
p=0,0024, indicative of a joint effect of FXIla and previous myocardial infarction in risk 
stratification. 
Conclusion: FXIla predicts future TnT positive cardiac events related to coronary plaque 
rupture and subsequent thrombosis in survivors of myocardial infarction. 
1177-94 Effect of a Single Dose of Aspirin (325 mg) on Plstelets 
in Human Volunteers With Mul t ip le  Risk Factors for 
Coronary Artery Disease 
Alexei I. Malinin, Kevin P. Callahan, Marcus E. McKenzie, Victor L Serebruany, Sinai 
Hospital, Johns Hopkins Universi~ Baltimore, Maryland. 
Background: Aspirin is beneficial for treatment and prevention of coronary artery disease, 
There are some data suggesting that platelet inhibition by aspirin is not exclusively 
related to prostaglandin blockade. We sought to determine how one pill of non-enteric 
coated aspirin (325-mg) affects human platelets in subjects with multiple risk factors for 
coronary artery disease. Methods: Data from 63 volunteers were analyzed. Platelets 
were assessed twice at baseline (pre-aspirin), and after 3-24 hours (post-aspirin). We 
employed 5~M epinephrine-induced conventional aggregometry, closure time with epi- 
nephrine/collagen cadddge by PFA-100~ (Dade-Behring, Inc), and aspirin reaction units 
stimulated by propyl gallat with Ultegre~ (Accumetdcs, Inc.) for measuring platelet func- 
tion, The expression of platelet receptors was determined by using the following mono- 
clonal antibodies: CD31, CD41, CD42b, CD51/CD61, CD62p, CD63, CDI07a, and 
CD151. PAC-1 was used to measure fibdnogen-platelet binding. Platelet-leukocyte for- 
mation was detected utilizing dual antibodies for a pan-platelet marker CD151, and 
CD14, a monocyte/macrophage marker. Results: A single tablet of aspirin significantly 
reduced platelet-rich plasma aggregation, and resulted in the decrease of aspirin reduc- 
tion units, and prolongation of the closure time. High correlation (r2=0.73-0.86) between 
platelet analyzers readings and aggregometry was observed. One pill of aspirin moder- 
ately inhibits expression of various surface platelet receptors measured, and such inhibi- 
tion reached significance (p<0.05) for CD31, CD41, CD42, CD62p, and CD151, and 
PAC-1. Conclusion: Aspirin exhibits direct effect on selective major platelet receptors 
challenging the postulate of exclusive prostanoid inhibition via platelet cyclooxygenase-1 
blockade. Apparently, independent additional mechanisms of aspidn anti-platelet proper- 
ties may be involved in high-risk patients for the development of coronary artery disease. 
Ultegra® Analyzer with a novel cartridge could be successfully used in clinical practice 
for monitoring of aspirin therapy efficacy, and early detection of aspirin resistance. 
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1178-82 Inotropic Effects of Selective ET-B Receptor Stimulation 
and Its Modulation by Endocardial Endothelium, NO, 
and Proataglandins 
Adelino F. Leite-Moreira, Carmen Brds-Silva, Carla A. Pedrosa, DpL Physiology, Faculty 
of Medicine, Porto, Portugal. 
Background. Endotbelin-1 (ET-1) is an endogenous peptide whose effects are mediated 
by ET-A and ET-B receptors. ET-A are responsible for the vasoconstrictor, positive ino- 
tropic and growth promoting properties of ET-1, while ET-B for its vasodilator and anti- 
mitogenic effects, presumably due to NO release, This study investigated the less well- 
known inotropic effects of selective ET-B stimulation, 
Methods. The study was performed in papillary muscles from New Zealand rabbits 
(n=25) and Wistar rats (n=33) (Krebs-Ringer; 1.8 mM Ca2+; 35°C). Effects of selective 
ET-B receptor activation by Sarafotoxin $6c (SRTX-c; 0.21~M) were evaluated in the 
absence (rabbit n=7; rat n= 8) and in the presence of NG-nitro-L-Arginine (L-NA; 90~M; 
rabbit n= 6; rat n=8), Indomethacin (INDO; I~M; rabbit n=6; rat n=8) and in muscles with- 
out endocardial endothelium (EE; rabbit n=6;rat n=9). Parameters for isometric contrac- 
tions included: active tension (AT) and peak rate of tension development (dT/dtmax). 
Only significant results (mean±SEM, p<0.05) are given, expressed as % change from 
baseline, 
Results. SRTX-c induced a negative inotropic effect, reducing AT (rabbit: 8.3±2.1%; rat: 
9.8±3.7%) and dT/dtmax (rabbit: 8.6±5.6%; rat: 8.9-z3.3%). In the rat, this effect was not 
influenced by L-NA (AT decreased 9.7+~?..8% and dT/dtmax 8.6+~2.9%), was blunted by 
INDO (AT decreased non-significantly 5.5+3,1% and dT/dtmax 7.2_+4.1%) and almost 
abolished when the EE was removed (AT decreased non-significantly 3.8±3.5% and dT/ 
dtmax 3.9±.3.5%). tn the rabbit, the negative inotropic effect of SRTX-c was reversed by 
L-NA (AT increased 22.8+_2,9 % and dT/dtmax 20.1+~?.,1%), by INDO (AT increased 
18,0!-_4.4 % and dT/dtmax 18.9±4.0%) and by EE removal (AT increased 35.2+11.7% 
and dT/dtmax 29.5±7.9%). 
Conclusions. Selective ET-B stimulation induces a negative inotropic effect both in rab- 
bit and rat myocardium, which is modulated by the EE. Damaging the EE reverses this 
effect in the rabbit and almost abolishes it in the rat. In the rabbit, EE modulation is pre- 
sumably mediated by NO and prostaglandins, while in the rat it seems to be only influ- 
enced by prostaglandins but not by NO. 
1178-83 Cocaine Increases Cardiac Ventricular Myocyte Protein 
Content by Protein Kinase C Dependent Mechanisms 
Robed J. Hennino, Yong Xian 9 Li, Adam Leon, University of South Florida College of 
Medicine, Tampa, Florida, James A, Haley VA Hospital, Tampa, Florida. 
BACKGROUND: Six million Americans regularly use cocaine, Chronic cocaine users 
have a 69% increase in LV muscle mass without associated increases in arterial pres- 
sure, heart rate, renin, aldosterone, norepinephrine, or cortisol. We determined whether 
cocaine directly increases the protein content of adult ventricular myocytes and if protein 
kinase C (PKC) is important in this process. METHODS: Adult rat cardiomyocytes were 
